Searched for
NOVARTIS PHARMACEUTICAL NEWS
Mystery deepens as FBI investigates missing US scientists; House Oversight Committee launches parallel probeA series of unexplained deaths and disappearances involving US scientists and government personnel, including a retired Air Force general, ...- Who are the US scientists linked to NASA and military research vanished or died under unexplained circumstancesA string of baffling deaths and disappearances among US scientists, including a retired Air Force general and NASA JPL researcher, has spar...
- US President Donald Trump to announce new deals to lower drug prices, White House saysPresident Trump is set to announce new agreements Friday aimed at lowering prescription drug prices, with major drugmakers like AbbVie, Bri...
- Novartis to acquire Avidity Biosciences for about $12 billionNovartis is acquiring U.S. biotech firm Avidity Biosciences for approximately $12 billion in cash to expand its rare disease treatment port...
- European shares tick higher after Friday selloff; Swiss stocks slumpEuropean shares edged higher on Monday, recovering some ground after a sharp selloff on Friday, while Swiss stocks slumped to their lowest ...
- Divi's Lab stock slips on US supply worries"While the exact revenue from Entresto-related supplies is undisclosed, it contributes a meaningful share to the overall business. However,...
- Fourth carcinogen discovered in heart pills used by millionsDMF, as the solvent is known, is classified by the World Health Organization as a probable carcinogen.
- Nikkei turns up, marks 4th day of gains on US-China trade hopesThe Nikkei share average ended 0.2 per cent higher to 21,464.23.
- FDI green light to spark M&As in pharma sectorUntil now to buy into an Indian enterprise, multinational drug companies needed an approval from FIPB under department of industrial policy...
- Despite being on rough end, annual report from US FDA’s OGD shows Indian firms won key approvals in 2015The annual report released by the FDA’s OGD shows Indian companies have won some key approvals in the world’s biggest pharmaceuticals marke...
- Sun Pharma gets boost with US FDA approval for GleevecSun Pharmaceutical announced it received approval from the US FDA for generic copies of Gleevec, a drug that treats chronic myeloid leukemi...
- Google's Life Sciences group is making another big move to treat diabetesGoogle Life Sciences entered a partnership with Sanofi, a European pharmaceutical company, to develop technologies to treat diabetes.
- Ranbaxy shares jump on approval of generic drug DiovanRanbaxy should be able to generate $190 million of sales and an after-tax profit of $100 million during 180 days, said a research analyst.
- Novartis buys GSK's cancer drugs for $14.5 billion in a 3-way dealThe collaboration between the two will create a new world-leading consumer healthcare business with $10 billion in annual sales.
- Dose of bitter pills, few booster injections for pharma sectorThe pharma sector, estimated to be around Rs 1.5 lakh cr, recorded single digit growth for the first time in many years on account of deepe...
- Poor growth of anti-infective segment remains a concern for pharmaceutical sectorThe latest growth numbers released for the month of February 2013 do not hold good news for the Indian pharma industry.
- Indian-origin executive among top new appointees at News CorpNews Corp today announced a major restructuring of its top management in line with its decision to split into two publicly traded firms.
- Jeremy Levin named as next CEO of Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries Ltd named Jeremy Levin of Bristol-Myers Squibb Coto to replace Shlomo Yanai as chief executive officer.
- Pharma cos shares extend gain on BSEShares of multinational pharmaceutical companies on Wednesday extended gains on the BSE, cheering their parents’ move to hike stake in thes...
- Of patents and pre-grant oppositionsOn January 25 this year, the patent office in Chennai rejected a patent application by pharma MNC Novartis for its anti-cancer drug Glivec ...
Load More
